Evidence map›Paper›PMID 39280204›Full record

ArticleJournal of obstetrics and gynaecology of India2024

New Paradigms in Cervical Cancer Prevention.

Usha B Saraiya

Abstract read
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Usha B SaraiyaBreach Candy Hospital, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical Cancer prevention is a relatively new concept in Medicine. Since mid-twentieth century, diagnosis of Precancerous phase became possible thus outcome of invasive cervical cancer could be avoided. The dawn of this new era began with the research on HPV infection, being the causative factor. Clinical use of vaccines made it possible to start primary prevention by the year 2006. There has been a paradigm shift in this field and some of the important shifts will be discussed. The 1st paradigm is to better understand "Cancer Prevention". Cytology or the "Pap Smear" as it is commonly known is a simple low cost, low technology test. Combining it with biomarker test gives it more validity. Angiogenesis of cervical neoplasia was based on colposcopy. Angiogenesis inhibitor was discovered on this concept which improved treatment results. Incidence and mortality of cervical cancer shows a global disparity. For this, we have to study the social determinants. Some of the causes leading to high mortality are delay in diagnosis and reaching healthcare facility. UN's SD goal has suggested 30% reduction to be achieved. HPV is the cause of many other cancers apart from cervical cancer which may lead to suffering and mortality. The most deadly genotypes of HPV are 9 which form the NONAVALENT Vaccine. Introduction of vaccine made in India may be a game changer. A new "Ray of Hope" was the introduction of therapeutic vaccines in 2020. It will reduce human suffering and prolong life. As research advances, many more new Paradigms will evolve.

Indexed as

Cervical cancerColposcopyHPV diseaseHPV vaccinesNew paradigmsPreventive oncology

Identifiers

PMID39280204
PMCPMC11399363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.